XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer
- 1 December 2006
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 103 (3) , 1031-1037
- https://doi.org/10.1016/j.ygyno.2006.06.016
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Estimating the world cancer burden: Globocan 2000International Journal of Cancer, 2001
- Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancerThe Lancet, 1997
- Comparative Study of the Patients with Locally Advanced Stages I and II Cervical Cancer Treated by Radical Surgery with and without Preoperative Adjuvant ChemotherapyGynecologic Oncology, 1995
- Neoadjuvant Chemotherapy with Vincristine and Cisplatin Followed by Radical Hysterectomy and Pelvic Lymphadenectomy for FIGO Stage IB Bulky Cervical Cancer: A Gynecologic Oncology Group Pilot StudyGynecologic Oncology, 1995
- The uses and limitations of DNA flow cytometry in stage IB or II cervical carcinomaCancer, 1993
- Results of a Prospective Randomized Trial with Neoadjuvant Chemotherapy in Stage IB, Bulky, Squamous Carcinoma of the CervixGynecologic Oncology, 1993
- Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survivalCancer, 1991
- A prospective surgical pathological study of stage I squamous carcinoma of the cervix: A Gynecologic Oncology Group studyGynecologic Oncology, 1989
- A possible new trend in the management of the carcinoma of the cervix uteriGynecologic Oncology, 1986